Background Progesterone administration has been shown to reduce the risk of preterm birth and neonatal morbidity in women at high risk, but there is uncertainty about longer term eff ects on the child.
Introduction
Several studies have assessed either vaginal progesterone or intramuscular 17α-hydroxyprogesterone caproate for the prevention of preterm birth in asymptomatic women with singleton pregnancy at high risk of preterm birth. An individual patient data meta-analysis of women with a short cervix showed that vaginal progesterone reduced the risk of preterm birth before 33 weeks (relative risk [RR] 0·58, 95% CI 0·42-0·80) and reduced a composite of neonatal mortality and morbidity (RR 0·57, 0·40-0·81). 1 Although there is debate whether vaginal and intramuscular therapies have similar mechanisms or effi cacy, the Cochrane Library meta-analysis groups the two treatments together, but reports separately for diff erent maternal risk groups. 2 Reduced risk of preterm birth before 34 weeks was shown in women with a short cervix (RR 0·64, 95% CI 0·45-0·90), without eff ect on perinatal mortality or neonatal death (perinatal mortality RR 0·74, 0·42-1·29; neonatal death RR 0·55, 0·26-1·13). 2 By contrast, in women with previous preterm birth, progestogens reduced the incidence of preterm birth (RR 0·31, 95% CI 0·14-0·69), perinatal mortality and neonatal death. 2 Although intramuscular 17α-hydroxyprogesterone caproate is licensed for women with a previous preterm birth, an independent analysis of data on vaginal progesterone for a US Food and Drug Administration advisory panel showed no benefi t, with the panel concluding that "the overall risk/benefi t profi le [is] not acceptable" to support approval of vaginal progesterone in women with a short cervix. 3 Despite recommendations for progesterone use 4 there are few data on long-term benefi t or safety for the baby beyond the neonatal period. Adverse childhood eff ects of preterm birth include neurodevelopmental and cognitive impairments, and increase with degree of prematurity. 5 Progesterone, by delaying birth and reducing prematurity, might reduce risk of impairment, but this could be off set by direct fetal harm by continuing prolonged exposure to intrauterine infection or infl ammation, commonly associated with preterm labour. Furthermore, therapies applied in pregnancy might have diff ering eff ects in the neonatal period and early childhood (benefi t in one and harm in another), as shown in the ORACLE II trial of antibiotics in spontaneous preterm labour 6, 7 and in trials of multiple doses of corticosteroids. 8 Hence, further information on childhood outcomes following progesterone treatment is required to determine the risk-benefi t ratio of this therapy.
Research in context
Evidence before this study Vaginal progesterone administration has been shown to reduce the risk of preterm birth and neonatal morbidity in women at high risk, but there is uncertainty about longer term eff ects on the child. We searched the Cochrane Pregnancy and Childbirth Group's Trials Register and the Cochrane Central Register of Controlled Trials (the Cochrane Library) until Feb 4, 2016, on MEDLINE (Jan 1, 1996, to Feb 4, 2016) , and PubMed (Jan 1, 1974, to Feb 4, 2016) using the terms "progesterone/ progestogen" AND "preterm birth prevention" AND "randomised trial" with no language restrictions. We also searched reference lists of trials and other review articles identifi ed from this initial search and from our records. We excluded women with multiple pregnancy and those with symptoms of preterm labour. We identifi ed two systematic reviews that compared preterm birth rates, neonatal outcomes, or childhood outcomes in women treated with progesterone or progestogens compared with those treated with placebo: a conventional meta-analysis published by the Cochrane collaboration and an individual patient data meta-analysis. No additional randomised trials were identifi ed which were not included in the Cochrane review. Neither of the meta-analyses reported on our three primary outcomes, those of fetal death or delivery, either occurring before 34 weeks and 0 days of gestation (obstetric primary outcome); a composite of death, bronchopulmonary dysplasia, and brain injury on cerebral ultrasound (neonatal primary outcome); or the Bayley-III cognitive composite score at 22-26 months of chronological age (childhood primary outcome). One individual patient data meta-analysis of women with a short cervix reported the eff ect of vaginal progesterone on the outcomes of preterm birth before 33 weeks (relative risk [RR] 0·58, 95% CI 0·42-0·80), and on a composite of neonatal mortality and morbidity (RR 0·57, 0·40-0·81). This individual patient data meta-analysis was restricted to women treated with vaginal progesterone. The Cochrane Library meta-analysis grouped women treated with any progestogen and reported on risk of preterm birth before 34 weeks review for women with a short cervix (RR 0·64, 95% CI 0·45-0·90), and on perinatal mortality (RR 0·74, 0·42-1·29) or neonatal death (RR 0·55, 0·26-1·13). Regarding women with a previous preterm birth, the Cochrane Library reported that progestogens reduced the incidence of preterm birth (RR 0·31, 95% CI 0·14-0·69), and both perinatal mortality (RR 0·50, 0·33-0·75) and neonatal death (RR 0·45, 0·27-0·76). Neither the individual patient data meta-analysis nor the Cochrane review were able to report on childhood outcomes, with the Cochrane review noting that "there is limited information available relating to longer-term infant and childhood outcomes, the assessment of which remains a priority".
Added value of this study
The OPPTIMUM study is, to our knowledge, the largest study to compare obstetric, neonatal, and childhood outcomes in high-risk women with singleton pregnancy treated with vaginal progesterone to prevent preterm birth. It is one of the few studies to look at childhood eff ects. In OPPTIMUM, by contrast with some of the published literature, vaginal progesterone was not signifi cantly associated with reduced risk either of preterm birth or of composite neonatal adverse outcomes. Additionally, progesterone had no signifi cant long-term benefi t or harm on outcomes in children at 2 years of age. The primary outcomes reported in OPPTIMUM were diff erent from the outcomes reported in the meta-analyses described above (and indeed diff erent from the primary outcomes in the source studies), hence meta-analysis of the evidence to provide a meaningful pooled estimate was not possible. We plan an individual patient data level analysis that will be able to address complexities such as diff erent inclusion criteria for the studies, diff erent progestogens used (vaginal progesterone or 17α-hydroxyprogesterone caproate), and the diff erences in outcome reporting.
Implications of all the available evidence
The fi ndings from OPPTIMUM are diff erent to some of those reported in the literature. For the fi rst time, we show childhood outcomes of progesterone to prevent preterm birth. The results of OPPTIMUM should prompt a major review of the use of progesterone for preterm birth prophylaxis, a search to identify specifi c women who might specifi cally benefi t, and a redoubling of eff orts to fi nd alternative strategies to prevent preterm birth in women at risk. Therefore, we did a double-blind randomised trial to determine whether vaginal progesterone prophylaxis given to reduce the risk of preterm birth aff ects neonatal and childhood outcomes.
Methods

Study design and participants
OPPTIMUM (dOes Progesterone Prophylaxis To prevent preterm labour IMprove oUtcoMe?) is a multicentre randomised double-blind placebo-controlled trial. Women were recruited from 65 UK National Health Service hospitals and one Swedish hospital. An abbreviated protocol has been published. 9 The study was granted approval by the Scotland A Research Ethics Committee (reference 08/MRE00/6). Clinical trials authorisation was given by the Medicines and Healthcare products Regulatory Agency (MHRA reference 22931/0009/001-0001 later revised to 01384/0208/001). A trial steering committee and a Data Monitoring Committee supervised the conduct of the study (appendix).
The study comprised a screening phase at 18-24 weeks and 0 days gestation and a treatment phase, starting at between 22 and 24 weeks of gestation. Written informed consent was obtained for both the screening phase (at 18-24 weeks and 0 days gestation) and treatment phase (between 22 and 24 weeks gestational age). All women had a singleton pregnancy, with gestational age established by ultrasound scan before 16 weeks, and were 16 years or older at screening. Women with clinical risk factors for preterm birth (any of a history in a previous pregnancy of preterm birth, or second trimester loss, or preterm premature fetal membrane rupture, or any history of a cervical procedure to treat abnormal smears) and a positive fetal fi bronectin test at 22-24 weeks of gestation were eligible for random allocation in the treatment phase from the beginning of the trial, and designated fi bronectin positive. After analysis of preliminary (masked) data in July, 2010, and the publication of a systematic review on screening for preterm birth, 10 we realised that our initial selection strategy erroneously missed women at medium-to-high risk of preterm birth. Thus, from Sept 1, 2010, after recruitment of the initial 84 women, fi bronectin-negative women with a history of spontaneous preterm birth at 34 weeks or less of gestation, or a cervical length of 25 mm or less were also eligible for inclusion, and designated a fi bronectin-negative group (see appendix for detailed inclusion and exclusion criteria and fi bronectin-positive or fi bronectin-negative group allocation). There are no nationally agreed recommendations on which pregnant women should be screened for preterm birth risk by measuring cervical length, nor did the OPPTIMUM protocol include recommendations on who should undergo cervical length screening, hence any such measurements were made by clinicians on an individual patient basis before the woman's recruitment to OPPTIMUM. A cervical length of 25 mm or less at any time between 18 and 24 weeks and 0 days gestation in the index pregnancy conferred eligibility for recruitment.
Randomisation and masking
Eligible women were allocated (1:1) to either progesterone 200 mg soft capsules (Utrogestan, Besins Healthcare) or an identical appearing placebo. Assignment to treatment allocation was done through a web portal hosted by the study data centre at the Robertson Centre for Biostatistics, at the Glasgow Clinical Trials Unit, University of Glasgow. The randomisation schedule was computer-generated at the Robertson Centre, using the method of randomised permuted blocks of length four, stratifi ed by history of a previous pregnancy of more than 14 weeks of gestation and by study centre. Allocation concealment was achieved by use of a placebo, which appeared identical to the active drug. Participants were asked for informed consent and enrolled by collaborating clinicians (listed in this Article and the appendix), who used the web portal described above to randomly assign participants to treatment. Treatment allocation corresponded to a box number in the local pharmacy, containing either active or placebo drug. Participants, investigators, pharmacists, and others involved in giving the intervention, assessing outcomes, or analysing data remained masked to treatment allocation until the end of the study. There was no formal attempt made to assess the success of masking.
Procedures
The participant administered the vaginal study medication daily at bedtime, commencing from about 22-24 weeks of gestation until 34 weeks or delivery of the baby, whichever was sooner. Co-administration of bromocriptine, rifamycin, ketoconazole, or ciclosporin was prohibited due to potential drug interactions. Rules for individual women to stop treatment on safety grounds (eg, after development of symptomatic placenta praevia) are defi ned in the protocol.
Compliance (assessed for each woman using a combination of medication pack returns, patient diaries, and patient self-reports) was calculated as the percentage of doses of study medication used divided by the expected doses. Adequate compliance was taken as 80% of prescribed medication.
Data were collected at screening, randomisation, 34 weeks of gestation, during labour and delivery, during the neonatal stay and at 1 and 2 years post-delivery to determine clinical outcomes. 2 year assessments, based on chronological age because of the mixed term and preterm population, were done at the local hospital clinic or at home. This assessment comprised the parent-completed structured clinical history, a parent-completed behavioural measure (the Strengths and Diffi culties Questionnaire) and the cognitive scale of the Bayley Scales of Infant and Toddler Development 3rd Edition (Bayley-III). All assessments were undertaken by See Online for appendix assessors who had received training, either from the study centre or via a national course; all met prespecifi ed criteria of 90% agreement or more on an item-by-item basis with an independent psychologist. Record forms were checked centrally for consistency and completeness. For children for whom we could not arrange a clinic assessment we requested information from the family doctor concerning general health and the presence of motor, sensory, and developmental concerns.
Outcomes
We defi ned three primary outcomes: either fetal death or delivery occurring before 34 weeks and 0 days of gestation (obstetric outcome); a composite of death, bronchopulmonary dysplasia, and brain injury on cerebral ultrasound (neonatal outcome); and the Bayley-III cognitive composite score at 22-26 months of chronological age (childhood outcome).
Brain injury was defi ned as any intraventricular haemorrhage (excluding subependymal haemorrhages), parenchymal cystic lesion or haemorrhagic lesion, or persistent ventriculomegaly (ventricular index >97th percentile). All scans were reported locally. All abnormal scans and 10% of normal scans were reviewed centrally masked to the local report (NM). Bronchopulmonary dysplasia (severe chronic lung disease) was defi ned as need for at least 30% oxygen or positive pressure (positive pressure ventilation or nasal continuous positive airway pressure) at 36 weeks postmenstrual age or discharge, whichever came fi rst.
Secondary effi cacy and safety outcomes were as follows: gestational age at delivery (weeks); deaths up to 2 years of age; death after trial entry up to the end of study; daily category of care after delivery room (normal or special or high dependency or intensive); surfactant administration; suspected or confi rmed necrotising entercolitis; neonatal infections (one or more discrete episodes with positive blood culture among those with infection, one or more discrete episodes with positive CNS culture among those with infection); maternal or child serious adverse events during pregnancy and birth; composite outcome of death or moderate-to-severe neurodevelopmental impairment at 2 years; moderate-to-severe neurodevelopmental impairment; individual components of disability; admissions to hospital during follow-up; behavioural scale scores at 2 years assessed in strengths and diffi culties questionnaire; change in EuroQol 5D (EQ-5D) from baseline to birth; change in EQ-5D from baseline to 12 months; and women's perception of treatment 1 month post-delivery (the proportion extremely or fairly satisfi ed). Outcomes were categorised as moderate or severe using published defi nitions. 11
Statistical analysis
A statistical analysis plan was fi nalised before data lock. Statistical analyses were done by C-MM and AM at the Robertson Centre for Biostatistics, Glasgow University according to the intention-to-treat principle. The three primary outcomes and secondary outcomes were compared between the treatment groups using mixed Figure: Trial profi le *Randomised in error, ineligible for treatment, and excluded post-randomisation. †Consent withdrawals for each of the phases refer to consent withdrawal at any time before reaching the outcome for that phase. ‡Losses to follow-up for each of the phases refer to losses to follow-up at any time before reaching the outcome for that phase. §Numbers with missing outcome data refer to each specifi c outcome only (obstetric, neonatal, and childhood) and are not additive across the stages since women can have outcome data for a later outcome. 15 eff ects logistic regression (or, for continuous variables, linear regression) models including treatment allocation and previous pregnancy (≥14 weeks) as fi xed eff ects, with study centre as a random eff ect. According to the prespecifi ed statistical analysis plan, p values were initially reported without adjustment for multiple comparisons, then adjusted using a Bonferroni-Holm procedure. 12 The planned sample size was around 1125 participants, depending on the relative numbers of fetal fi bronectinpositive and fetal fi bronectin-negative women recruited. 9 Detailed sample size calculations are available in the published protocol, but in brief the study had at least 80% power to detect what was considered the minimal important clinical diff erence for each of the three primary outcomes at a nominal 5% level of signifi cance. 9 Sensitivity analyses included repeating the primary analyses in a per-protocol dataset (which excluded data from women who were found not to be compliant with the inclusion or exclusion criteria, or who had a structural or chromosomal fetal anomaly discovered after inclusion, or who had a multiple pregnancy discovered after inclusion or who were not adequately compliant with treatment by the prespecifi ed defi nition), and the use of multiple imputation of missing primary outcome data. Preplanned subgroup analyses for primary outcomes were done by extending the main regression models to include interaction terms for the following subgroups: fi bronectin positive or fi bronectin negative, cervical length of at most 25 mm or longer than 25 mm, cervical length of at most 15 mm or longer than 15 mm, chorioamnionitis yes or no, history of spontaneous preterm birth or no such history, and history of preterm birth or no such history. Safety outcomes (adverse events) were assessed in a safety population, excluding women for whom it was documented that no study medication was taken. This trial is registered with ISRCTN.com, number ISRCTN14568373.
Role of the funding source
Neither the funders of the study nor the provider of active and placebo medication had any role in study design, data collection, data analysis, data interpretation, or writing of the report. C-MM and AM had full access to all the data in the study and JEN had fi nal responsibility for the decision to submit for publication.
Results
We reviewed the case notes of 15 132 women for eligibility, between Feb 2, 2009, and April 12, 2013. 1228 (8%) were subsequently randomly assigned, 610 allocated to placebo and 618 to progesterone (fi gure). Two of these women were randomised in error and were excluded from initiating on treatment and the intention-to-treat population. Baseline characteristics of participants in the intention-to-treat population were balanced across the two allocated groups (table 1). The number of women randomly assigned per site ranged from one to 165; three sites screened but did not randomly assign participants. Information on the obstetric, neonatal, and childhood primary outcomes was available for 1197 (97%), 1176 (96%), and 869 (71%) of participants, respectively. There were few diff erences in baseline characteristics between those for whom primary outcome data was or was not available (appendix).
Information from diary returns for 1011 (82%) women showed 80% or more compliance in 361 (71%) of 509 in the placebo group and 333 (66%) of 502 in the progesterone group. For compliant women, the median percentage of medication taken was 92·3% (IQR 71·6-98·7) and 92·9% (59·0-98·6), respectively. No woman terminated treatment because of prespecifi ed discontinuation rules.
Although the point estimate of the odds ratio (OR) was in the direction of benefi t, administration of progesterone did not signifi cantly alter the risk of the obstetric (fetal death or birth before 34 weeks) or neonatal (a composite of death, brain injury, or bronchopulmonary dysplasia) Binary outcomes are n/N (%) and continuous outcomes are mean (SD). *CI for odds ratio (OR) and p value adjusted for multiple primary outcomes using Bonferroni-Holm method. †Median weeks of age at assessment: 111·6 weeks (IQR 104·6-122·2) in the placebo group and 110·4 weeks (104·0-121·5) in the progesterone group. ‡Sample size of 439 in the placebo group and 430 in the progesterone group and includes imputations for deaths. §Difference in means (95% CI). ¶Unadjusted for previous pregnancy of at least 14 weeks because of small sample size. ||Bronchopulmonary dysplasia defi ned as need for at least 30% oxygen to maintain oxygen saturation above 92% or positive pressure (positive pressure ventilation or nasal continuous positive airway pressure) at 36 weeks postmenstrual age or discharge, whichever comes fi rst. **Brain injury on ultrasound scan defi ned as any intraventricular haemorrhage (excludes subependymal haemorrhages), parenchymal cystic or haemorrhagic lesion, or persistent ventriculomegaly (ventricular index >97th percentile); the components of the brain scan abnormalities were: intraventricular haemorrhage 13 (3%) of 383 patients and seven (2%) of 357 patients, parenchymal cystic or haemorrhagic lesion 23 (6%) of 382 and eight (2%) of 357, and persistent ventriculomegaly (>97th percentile) eight (2%) of 372 and three (1%) of 349 in the placebo group and the progesterone group, respectively. Childhood outcome -0·91* (-5·92 to 4·11); 0·724 187 -0·37* (-2·96 to 2·23); 0·782 681 0·85 Logistic or linear mixed eff ects regression models predicting outcome from treatment, subgroup and the interaction of treatment with the subgroup variable, adjusting for previous pregnancy of at least 14 weeks and a random eff ect for study centre. *Mean diff erence. outcome after the prespecifi ed adjustment for multiple comparisons (Bonferroni-Holm procedure): OR 0·86 (95% CI 0·61-1·22) for the obstetric outcome and OR 0·62 (0·38-1·03) for the neonatal outcome (table 2) . Similarly, there was no eff ect on childhood outcomes (cognitive score 97·7 [SD 17·5] for placebo and 97·3 [17·9] for progesterone; diff erence in means -0·48, adjusted 95% CI -2·77 to 1·81). Among the components of the primary obstetric and neonatal outcomes, the proportion of babies with observed neonatal brain injuries on cerebral ultrasound scanning was lower in the progesterone group (18 [3%] of 584 vs 34 [6%] of 574; OR 0·50, 95% CI 0·31-0·84; table 2). A reduction in brain injury was also observed in a sensitivity analysis restricted to participants in whom a neonatal brain scan was done (n=776; OR 0·54, 95% CI 0·32-0·88). Neonatal death was also less common in the progesterone group, but the low numbers precluded planned adjustment for the covariate previous pregnancy at 14 weeks or longer gestation.
Similar results for primary outcomes were achieved in per-protocol analyses (687 [56%] of 1226 patients in the intention-to-treat population; appendix); in analyses with multiple imputations of missing data on the primary outcomes (appendix); and in alternative multiple comparison procedures, including the Sidak-Holm method and permutation adjustment (50 000 permutations; data not shown). Comparison of characteristics of women included and not included in the per-protocol analysis are shown in the appendix. An additional sensitivity analysis with imputations for the variable smoking was done post hoc because of the diff erence in smoking prevalence in those with and without outcome data: again this generated similar results to the main analysis (data not shown). A post-hoc survival curve of time to death or delivery (primary obstetric outcome) showed that the diff erences between the progesterone and placebo groups appeared greatest at our prespecifi ed gestational cutoff of 34 weeks (appendix).
Rates of preterm birth were higher in the predefi ned subgroups of women with a positive fetal fi bronectin test, women with a cervical length of at most 25 mm, and women with a cervical length of at most 15 mm (appendix). However, there were no signifi cant interactions between these groups and the eff ect of progesterone on any of the obstetric, neonatal, or childhood outcomes. Within subgroups there was no signifi cant eff ect of progesterone on any of the primary obstetric or childhood outcomes (table 3) . The interaction term approached statistical signifi cance (p=0·053) for the neonatal outcome in the subgroup with a history of a previous spontaneous preterm birth, in which the OR for the neonatal outcome was lower in the progesterone group (0·48, 95% CI 0·29-0·79) compared with the complementary group with no previous spontaneous preterm birth (1·22, 0·55-2·71). However, caution is needed in interpreting all these fi ndings given the number of prespecifi ed subgroup analyses undertaken on three primary outcomes.
Placebo group
Progesterone group N n (%) or mean (SD)* N n (%) or mean (SD)* Most of the other secondary outcomes did not diff er statistically between progesterone and placebo groups (table 4). Although neurodevelopmental impairments were similarly distributed in each group, somatic impairments in renal, gastrointestinal, and respiratory systems though of low frequency, were more common in the progesterone group. There were no apparent diff erences in the proportions with safety or other outcomes between the placebo and progesterone groups (table 5).
Pregnancy complications
Maternal
Discussion
OPPTIMUM is the largest randomised trial of vaginal progesterone for prevention of preterm birth in women at high risk. By contrast with published reports, [13] [14] [15] we show no eff ect of progesterone on rates of either preterm birth or neonatal composite outcome. For the fi rst time using a direct assessment, we provide strong evidence that the use of progesterone from 22-24 to 34 gestational weeks has no demonstrable eff ect on 2 year neuro developmental outcomes, either as cognitive scores or impairments, suggesting that progesterone prophylaxis to prevent preterm birth appears safe for the baby (at least up to 2 years of age). Only one previous study has determined long-term eff ects of progestogens given to singleton pregnancies in a randomised trial of intra muscular 17α-hydroxyprogesterone caproate, 16, 17 but this study used parent report and had a smaller sample size with a higher proportion lost to follow-up. The other published studies are restricted to questionnaire or health record-based assessments in twins whose mothers were enrolled in randomised trials of progesterone versus placebo. 18, 19 OPPTIMUM was a pragmatic trial, set up to examine eff ects of progesterone on outcomes in a heterogeneous group of women at risk of preterm birth. We extended our recruitment criteria early in the study, when newly available information suggested we were missing women at high risk of preterm birth. Notably, the fi bronectinnegative group recruited under the extended criteria, had rates of the primary outcome (death or preterm birth before 34 weeks) of 13% (appendix), some three times those of the background population of pregnant women in the UK. 20 Hence, our decision to extend the recruitment criteria appears correct. Importantly, although we were able to defi ne at baseline subgroups of women with higher rates of preterm birth (including those with a short cervix and those with a positive fi bronectin test), our data suggest that the effi cacy of progesterone (for all outcomes) is similar across groups. Therefore, our data do not support the premise that vaginal progesterone is specifi cally eff ective in women with a short cervix.
Although we showed no overall eff ect, point estimates of the reduction in the odds of the obstetric outcome (0·86) and the neonatal composite outcome (0·62) are in the direction of benefi t, but with CIs that show no advantage. Additionally, point estimates in the short cervix subgroups are similar to those reported in metaanalyses of the eff ect of progesterone in such women. For example, the OR for preterm birth prevention was 0·69 in OPPTIMUM, compared with a RR of 0·64 (before 34 weeks) in one systematic review 21 and a RR of 0·58 (before 33 weeks) in an individual patient data meta-analysis. 1 The corresponding fi gures for eff ects on a neonatal composite are OR 0·54 in OPPTIMUM and RR 0·57 in the individual patient data meta-analysis. 1 An individual patient data meta-analysis, including the OPPTIMUM fi ndings, to understand what the totality of evidence indicates, particularly within subgroups of interest, is likely to be helpful.
Although we have shown no signifi cant eff ect on the overall neonatal composite outcome, there appeared to be a reduction in neonatal brain injury. Progesterone-associated reduction in brain injury is plausible given supportive preclinical data in adult models showing potentially neuroprotective eff ects of reduced infl ammatory cytokine production, reduced activation of microglial cells, and limited apoptosis, 22, 23 although a recent trial of over 1000 adult participants with traumatic brain injury has shown no clinical therapeutic eff ect. 24 However, in the absence of long-term improvements in cognitive function, a protective eff ect of progesterone on brain injury (defi ned by ultrasound) might not be important clinically: not only was brain injury on ultrasound a relatively rare event in OPPTIMUM but other studies have shown no correlation between this fi nding and longer term neurosensory impairment. 25 Additionally, these non-signifi cant reductions in the neonatal composite adverse outcome need to be considered against the non-signifi cant increase in the childhood adverse outcome of death or moderate-to-severe neurodevelopmental impairment. OPPTIMUM strongly suggests that the effi cacy of progesterone in improving outcomes is either nonexistent or weak. Given the heterogeneity of the preterm labour syndrome we cannot exclude benefi t in specifi c phenotypic or genotypic subgroups of women at risk. However, the subgroups of women who might benefi t do not appear to be easily identifi able by current selection strategies, including cervical length measurement and fi bronectin testing.
Reassuringly, our study suggests that progesterone is safe for those who wish to take it for preterm birth prophylaxis. The overall rate of maternal or child adverse events was similar in the progesterone and placebo groups. There were few diff erences in the incidence of adverse secondary outcomes in the two groups, with the exception of a higher rate of renal, gastrointestinal, and respiratory complications in childhood in the progesterone groups. Importantly, the absolute rates of these complications was low. Follow-up of other babies exposed in utero to vaginal progesterone would be helpful in determining whether the increased rate of some renal, gastrointestinal, and respiratory complications is a real eff ect or a type I error.
A potential weakness in our trial is that overall compliance was only 69%. This contrasts with a reported compliance of 88·5% in the study by Hassan and colleagues, 13 but is greater than the compliance seen in routine clinical practice. 26 Additionally, the assumption in the Hassan study that women who did not return study medication were fully compliant might have erroneously infl ated their estimate of compliance. No information on compliance was reported in the other large study on vaginal progesterone in singletons. 15 Notably, in OPPTIMUM, the eff ect size for each of the primary outcomes was very similar in the per-protocol analysis (restricted to those with adequate treatment compliance) compared with the intention-to-treat group, suggesting that suboptimum compliance did not have a major eff ect on overall results.
We believe that OPPTIMUM should prompt a major review of the use of progesterone for preterm birth prophylaxis, a search to identify specifi c women who might specifi cally benefi t, and a redoubling of eff orts to fi nd alternative strategies to prevent preterm birth in women at risk. For those clinicians and women who wish still to use progesterone for preterm birth prophylaxis, our data provide reassurance that it appears safe, at least until 2 years of age of the child.
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